Pricing Log in Create free account

IN8bio, Inc. (INAB) vs NKGen Biotech, Inc. (NKGN)

IN8bio, Inc. and NKGen Biotech, Inc. are both Biotechnology companies. IN8bio, Inc. and NKGen Biotech, Inc. are of similar size ($8.8M and $8.2M). Across the 9 metrics below, IN8bio, Inc. leads on 5 and NKGen Biotech, Inc. on 4.

Valuation

Metric INAB NKGN Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.99 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (231.18%) (10,600.00%) (32.88%)
Free cash flow yield (80.81%) (4,296.38%) (23.13%)

Profitability

Metric INAB NKGN Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (111.11%) 44.70% (51.96%)
Return on assets (90.80%) (146.49%) (46.06%)
Return on invested capital (2,948.56%) 0.00% 0.00%

Growth

Metric INAB NKGN Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 74.06% 71.38% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric INAB NKGN Biotechnology median
Debt to equity 0.00 (0.59) 0.00
Current ratio 8.21 0.05 4.97
Net debt to EBITDA 1.56 (1.69) 1.01

Dividend

Metric INAB NKGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INAB NKGN Biotechnology median
Market cap 8.19m 8.76m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack